Workflow
Clinical drug development for pulmonary diseases
icon
搜索文档
Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript
Seeking Alpha· 2026-09-29 08:43
Conversation I will now turn the call over to Dr. Brigette Roberts, Chief Corporate Affairs Officer and Board member at Quince Therapeutics. Please go ahead, Brigette. Good afternoon, and welcome to the Quince Therapeutics Virtual KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be available on the company website following the conclusion of the event. Brigette Roberts Chief Corporate Affairs Officer & Director Thank you, Wilson. So good afternoon, everyone, a ...